A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)
NCT ID: NCT02425891
Last Updated: 2022-07-19
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
902 participants
INTERVENTIONAL
2015-06-23
2021-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)
NCT03125902
A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer
NCT03197935
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
NCT03498716
A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
NCT03800836
A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
NCT04177108
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Atezolizumab Plus Nab-Paclitaxel
Participants assigned to atezolizumab plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.
Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody
Atezolizumab at a fixed dose of 840 milligrams via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
Nab-Paclitaxel
Nab-Paclitaxel at a starting dose of 100 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle. Nab-Paclitaxel was administered for a target of at least 6 cycles, with no maximum in the absence of disease progression or unacceptable toxicity.
Placebo Plus Nab-Paclitaxel
Participants assigned to placebo plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.
Nab-Paclitaxel
Nab-Paclitaxel at a starting dose of 100 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle. Nab-Paclitaxel was administered for a target of at least 6 cycles, with no maximum in the absence of disease progression or unacceptable toxicity.
Placebo
Placebo administered via IV infusion on Days 1 and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody
Atezolizumab at a fixed dose of 840 milligrams via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
Nab-Paclitaxel
Nab-Paclitaxel at a starting dose of 100 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle. Nab-Paclitaxel was administered for a target of at least 6 cycles, with no maximum in the absence of disease progression or unacceptable toxicity.
Placebo
Placebo administered via IV infusion on Days 1 and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No prior chemotherapy or targeted systemic therapy for inoperable locally advanced or metastatic TNBC
* Eligible for taxane monotherapy (i.e., absence of rapid clinical progression, life-threatening visceral metastases, or the need for rapid symptom and/or disease control)
* A representative formalin-fixed, paraffin-embedded tumor specimen in paraffin blocks, or at least 20 unstained slides with an associated pathology report documenting ER, PR, and HER2 negativity. Participants with fewer than 20 unstained slides available at baseline, and not fewer than 12 unstained slides will be eligible upon discussion with Medical Monitor
* Eastern Cooperative Oncology Group performance status of 0 or 1
* Measurable disease as defined by RECIST v1.1
* Adequate hematologic and end-organ function
Exclusion Criteria
* Leptomeningeal disease
* Pregnancy or lactation
* History of autoimmune disease
* Prior allogeneic stem cell or solid organ transplantation
* Positive test for human immunodeficiency virus
* Active hepatitis B or hepatitis C
* Receipt of a live, attenuated vaccine within 4 weeks prior to randomization, during treatment, or within 5 months following the last dose of atezolizumab/placebo
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham
Birmingham, Alabama, United States
Highlands Oncology Group
Springdale, Arkansas, United States
Kaiser Permanente of Northern California
Oakland, California, United States
Emad Ibrahim, Md, Inc
Redlands, California, United States
Univ of Calif, San Francisco; Breast Cancer Center
San Francisco, California, United States
Kaiser Permanente - San Marcos
San Marcos, California, United States
Cancer Research Collaboration, Inc.
Santa Ana, California, United States
Stanford Univ School of Med; Oncology
Stanford, California, United States
Kaiser Permanente Of Colorado
Aurora, Colorado, United States
Yale Cancer Center; Medical Oncology
New Haven, Connecticut, United States
Norwalk Hospital
Norwalk, Connecticut, United States
Stamford Hospital; BCC, MOHR
Stamford, Connecticut, United States
MedStar Georgetown University Hospital (Lombardi Comprehensive Cancer Center)
Washington D.C., District of Columbia, United States
Florida Cancer Specialists - SCRI; Pharmacy
Fort Myers, Florida, United States
Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy)
Jacksonville, Florida, United States
The Mount Siani Comprehensive Cancer Center
Miami Beach, Florida, United States
Florida Cancer Research Institute
Plantation, Florida, United States
Florida Cancer Specialists (St. Petersburg - St. Anthony's Professional Building)
St. Petersburg, Florida, United States
Northwest Georgia Oncology Centers PC - Marietta
Marietta, Georgia, United States
Rush University Medical Center - Chicago
Chicago, Illinois, United States
Mercy Medical Center
Baltimore, Maryland, United States
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States
Maryland Oncology Hematology
Rochville, Maryland, United States
Barbara Ann Karmanos Cancer Institute; Oncology
Detroit, Michigan, United States
West Michigan Cancer Center
Kalamazoo, Michigan, United States
Jackson Oncology Associates, PLLC
Jackson, Mississippi, United States
Health Midwest Ventures Group, Inc d/b/a HCA MidAmerica Division, LLC
Kansas City, Missouri, United States
Washington University School of Medicine
St Louis, Missouri, United States
New Hampshire Hematology Oncology
Manchester, New Hampshire, United States
The Valley Hospital
Ridgewood, New Jersey, United States
ProHEALTH Care Associates LLP
Lake Success, New York, United States
Laura and ISAAC Perlmutter Cancer Center at NYU Langone.
New York, New York, United States
Montefiore Medical Center
The Bronx, New York, United States
Onc/Hem Care Clin Trials LLC
Cincinnati, Ohio, United States
The Mark H. Zangmeister Ctr; Mid Ohio Onc/Hem Inc.
Columbus, Ohio, United States
Kaiser Perm NW - Rheuma
Portland, Oregon, United States
Providence Cancer Center
Portland, Oregon, United States
St. Luke's Cancer Care Associates
Bethlehem, Pennsylvania, United States
Magee Womens Hospital
Pittsburgh, Pennsylvania, United States
Greenville Health System (GHS) Cancer Institute
Greenville, South Carolina, United States
Wellmont Bristol Regional Medical Center
Bristol, Tennessee, United States
West Clinic
Germantown, Tennessee, United States
Sarah Cannon Cancer Center - Tennessee Oncology, Pllc
Nashville, Tennessee, United States
Vanderbilt
Nashville, Tennessee, United States
Texas Oncology- El Paso Cancer Treatment Center Gateway
El Paso, Texas, United States
The Methodist Cancer Center
Houston, Texas, United States
University of Texas;M.D. Anderson Cancer Center
Houston, Texas, United States
Inova Medical Group
Fairfax, Virginia, United States
Cancer Care Northwest
Spokane, Washington, United States
Centro de Oncologia e Investigacion Buenos Aires (COIBA)
Buenos Aires, , Argentina
Fundación CENIT para la Investigación en Neurociencias
Buenos Aires, , Argentina
Centro Oncologico Riojano Integral (CORI)
La Rioja, , Argentina
Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia
Nepean Cancer Care Centre
Sydney, New South Wales, Australia
Icon Cancer Foundation
South Brisbane, Queensland, Australia
Princess Alexandra Hospital; Division of Cancer Services
Woolloongabba, Queensland, Australia
Peninsula and South Eastern Haematology and Oncology Group
Frankston, Victoria, Australia
Peter MacCallum Cancer Centre; Medical Oncology
Melbourne, Victoria, Australia
Sunshine Hospital
St Albans, Victoria, Australia
St John of God Hospital; Bendat Cancer Centre
Subiaco, Western Australia, Australia
Lkh-Univ. Klinikum Graz; Klinik Für Innere Medizin I
Graz, , Austria
Ordensklinikum Linz Barmherzige Schwestern; Abt. fur Innere Medizin 1
Linz, , Austria
A.Ö. Lhk; Ii. Medizinische Abt. Mit Schwerpunkt Gaströnter. & Onkologie
Steyr, , Austria
Medizinische Universität Wien; Univ.Klinik für Innere Medizin I
Vienna, , Austria
Institut Jules Bordet
Anderlecht, , Belgium
Cliniques Universitaires St-Luc
Brussels, , Belgium
GHdC Site Notre Dame
Charleroi, , Belgium
AZ Groeninge
Kortrijk, , Belgium
UZ Leuven Gasthuisberg
Leuven, , Belgium
Sint Augustinus Wilrijk
Wilrijk, , Belgium
Clinic of Oncology, University Clinical Center Sarajevo
Sarajevo, , Bosnia and Herzegovina
Crio - Centro Regional Integrado de Oncologia
Fortaleza, Ceará, Brazil
Santa Casa de Misericordia de Salvador
Salvador, Estado de Bahia, Brazil
Hospital Araujo Jorge; Departamento de Ginecologia E Mama
Goiânia, Goiás, Brazil
Hospital de Caridade de Ijui; Oncologia
Ijuí, Rio Grande do Sul, Brazil
Hospital das Clinicas - UFRGS
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Sao Lucas - PUCRS
Porto Alegre, Rio Grande do Sul, Brazil
Centro de Pesquisas Oncologicas - CEPON
Florianópolis, Santa Catarina, Brazil
Clinica de Neoplasias Litoral
Itajaí, Santa Catarina, Brazil
Hospital Perola Byington
São Paulo, São Paulo, Brazil
Hospital Sao Jose
São Paulo, São Paulo, Brazil
Tom Baker Cancer Centre-Calgary
Calgary, Alberta, Canada
Cross Cancer Institute ; Dept of Medical Oncology
Edmonton, Alberta, Canada
BC Cancer - Kelowna (Sindi Ahluwalia Hawkins Centre)
Kelowna, British Columbia, Canada
British Columbia Cancer Agency (Bcca) - Vancouver Cancer Centre
Vancouver, British Columbia, Canada
Queen Elizabeth II Health Sciences Centre; Oncology
Halifax, Nova Scotia, Canada
Kingston General Hospital
Kingston, Ontario, Canada
Lakeridge Health Oshawa; Oncology
Oshawa, Ontario, Canada
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada
Sunnybrook Odette Cancer Centre
Toronto, Ontario, Canada
Jewish General Hospital
Montreal, Quebec, Canada
Hopital du Saint Sacrement
Québec, Quebec, Canada
Centro de Cancer Pontificie Universidad Catolica de Chile
Santiago, , Chile
Sociedad de Investigaciones Medicas Ltda (SIM)
Temuco, , Chile
Clinica del Country
Bogotá, , Colombia
Oncomedica S.A.
Montería, , Colombia
Clinica CIMCA
San José, , Costa Rica
ICIMED Instituto de Investigación en Ciencias Médicas
San José, , Costa Rica
Fakultni nemocnice Olomouc; Onkologicka klinika
Olomouc, , Czechia
Fakultni Poliklinika Vseobecne Fakultni Niemocnice; Onkologicka Klinika
Prague, , Czechia
Fakultni nemocnice v Motole
Prague, , Czechia
North Estonia Medical Centre Foundation; Oncology Centre
Tallinn, , Estonia
Tartu Uni Hospital; Hematology - Oncology Clinic
Tartu, , Estonia
Tampere University Hospital; Dept of Oncology
Tampere, , Finland
Ico - Paul Papin
Angers, , France
Institut Sainte Catherine
Avignon, , France
Hopital Jean Minjoz
Besançon, , France
HOPITAL MICHALLON - CENTRE HOSPITALIER UNIVERSITAIRE DE GRENOBLE, Service d'oncologie Médicale
Grenoble, , France
Centre Oscar Lambret
Lille, , France
Centre Leon Berard
Lyon, , France
Institut régional du Cancer Montpellier
Montpellier, , France
Clinique Catherine de Sienne
Nantes, , France
Institut Curie
Paris, , France
Hopital La Pitie Salpetriere
Paris, , France
Institut De Cancerologie De L'Ouest; Medical Oncology
Saint-Herblain, , France
Centre Paul Strauss
Strasbourg, , France
Ambulantes Tumorzentrum Spandau; Dres. Benno Mohr und Uwe Peters
Berlin, , Germany
St. Elisabeth-Krankenhaus; Brustzentrum
Cologne, , Germany
St. Johannes Hospital; Abt. für Hämatologie und Onkologie
Dortmund, , Germany
Universitätsklinikum "Carl Gustav Carus" der Technischen Universität Dresden
Dresden, , Germany
Universitätsklinikum Erlangen; Frauenklinik
Erlangen, , Germany
Uniklinik Essen; Gynäkologie
Essen, , Germany
Niels-Stensen-Kliniken Franziskus-Hospital Harderberg GmbH
Georgsmarienhütte, , Germany
Universitätsklinikum Halle (Saale); Universitätsklinik Und Poliklinik Für Gynäkologie
Halle, , Germany
Universitätsklinikum Hamburg-Eppendorf; Frauenklinik
Hamburg, , Germany
Facharztzentrum Eppendorf, Studien GbR
Hamburg, , Germany
Universitatsklinik Heidelberg; Universitätshautklinik und Nationales Centrum für Tumorerkrankungen
Heidelberg, , Germany
Praxis Köppler, Heymann, Weide, Thomalla; Fä Für Innere Medizin
Koblenz, , Germany
Universitätsklinikum Schleswig-Holstein; Campus Lübeck
Lübeck, , Germany
Klinikum rechts der Isar der TU München; Klinik und Poliklinik für Frauenheilkunde
München, , Germany
Gemeinschaftspraxis für Hämatologie und Onkologie
Münster, , Germany
MVZ Nordhausen gGmbH, Praxis Dr. Grafe
Nordhausen, , Germany
Oncologianova GmbH - Gesellschaft für Innovationen in der Onkologie
Recklinghausen, , Germany
Mutterhaus der Borromäerinnen gGmbH, Abteilung Hämatologie-Onkologie
Trier, , Germany
Dres. Helmut Forstbauer, Carsten Ziske und Kollegen; Onkologische Schwerpunktpraxis
Troisdorf, , Germany
Universitätsklinik Tübingen; Frauenklinik & Poliklinik
Tübingen, , Germany
Anticancer Hospital Ag Savas; 1St Dept of Internal Medicine
Athens, , Greece
IASO General Hospital of Athens
Athens, , Greece
Univ General Hosp Heraklion; Medical Oncology
Heraklion, , Greece
University Hospital of Patras Medical Oncology
Pátrai, , Greece
Euromedical General Clinic of Thessaloniki; Oncology Department
Thessaloniki, , Greece
Grupo Angeles
Guatemala City, , Guatemala
Queen Mary Hospital; Dept of Medicine
Hong Kong, , Hong Kong
Orszagos Onkologiai Intezet; B Belgyogyaszati Osztaly
Budapest, , Hungary
Fövárosi Önkormányzat uzsoki utcai Kórház
Budapest, , Hungary
Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont
Szeged, , Hungary
Istituto Nazionale Tumori Irccs Fondazione g. PASCALE;U.O.C. Oncologia Medica Senologica
Napoli, Campania, Italy
Irccs Istituto Europeo Di Oncologia (IEO); Ricerca Di Senologia Medica
Milan, Lombardy, Italy
Aichi Cancer Center Hospital
Aichi, , Japan
Fukushima Medical University Hospital
Fukushima, , Japan
Gunma Prefectural Cancer Center
Gunma, , Japan
Hiroshima City Hiroshima Citizens Hospital
Hiroshima, , Japan
Hiroshima University Hospital
Hiroshima, , Japan
National Hospital Organization Hokkaido Cancer Center
Hokkaido, , Japan
Hyogo Medical University Hospital
Hyōgo, , Japan
Sagara Hospital
Kagoshima, , Japan
St. Marianna University Hospital
Kanagawa, , Japan
Tokai University Hospital
Kanagawa, , Japan
Kumamoto University Hospital
Kumamoto, , Japan
Kyoto University Hospital
Kyoto, , Japan
Mie University Hospital
Mie, , Japan
Tohoku University Hospital
Miyagi, , Japan
Niigata Cancer Center Hospital
Niigata, , Japan
Okayama University Hospital
Okayama, , Japan
Naha-nishi Clinic
Okinawa, , Japan
National Hospital Organization Osaka National Hospital
Osaka, , Japan
Osaka International Cancer Institute
Osaka, , Japan
Kindai University Hospital
Osaka, , Japan
Saitama Medical University International Medical Center
Saitama, , Japan
Saitama Cancer Center
Saitama, , Japan
Shizuoka Cancer Center
Shizuoka, , Japan
National Cancer Center Hospital
Tokyo, , Japan
St. Luke's International Hospital
Tokyo, , Japan
Komagome Hospital
Tokyo, , Japan
The Cancer Institute Hospital of JFCR
Tokyo, , Japan
Daugavpils Regional Hospital
Daugavpils, , Latvia
Riga East Clinical University Hospital Latvian Oncology Centre
Riga, , Latvia
Centro Medico Dalinde
Mexico City, Mexico CITY (federal District), Mexico
Centro Médico Zambrano Hellion
Monterrey, Nuevo León, Mexico
Instituto Estatal de Cancerologia Colima
Colima, , Mexico
Iem-Fucam
D.F., , Mexico
Consultorio de Medicina Especializada; Dentro de Condominio San Francisco
Mexico City, , Mexico
Helse Bergen HF Haukeland universitetssjukehus kreftavdelingen poliklinikk
Bergen, , Norway
Sørlandet Sykehus Kristiansand
Kristiansand, , Norway
Stavanger Universitetssykehus, Helse Stavanger HF
Stavanger, , Norway
Centro Oncológico de Panamá
Panama City, , Panama
Centrum Onkologii w Bydgoszczy; Oddzial Kliniczny Onkologii
Bydgoszcz, , Poland
Szpitale Wojewodzkie w Gdyni Sp. z o.o.
Gdynia, , Poland
Szpital Uniwersytecki w Krakowie, Oddział Kliniczny Kliniki Onkologii
Krakow, , Poland
Centrum Onkologii Ziemi LUBELSKIEJ im. Sw Jana z Dukli, I oddz. Chemioterapii
Lublin, , Poland
Narodowy Inst.Onkologii im.Sklodowskiej-Curie Panstw.Inst.Bad; Klinika Nowtw.Piersi i Chir.Rekonstr
Warsaw, , Poland
Wojskowy Instytut Medyczny
Warsaw, , Poland
Oncomed SRL
Timișoara, , Romania
Arkhangelsk Regional Clinical Oncology Dispensary
Arkhangelsk, Arhangelsk, Russia
Moscow City Oncology Hospital #62
Moscovskaya Oblast, Moscow Oblast, Russia
Main Military Clinical Hospital named after N.N. Burdenko
Moscow, Moscow Oblast, Russia
Blokhin Cancer Research Center; Combined Treatment
Moskva, Moscow Oblast, Russia
Ivanovo Regional Oncology Dispensary
Ivanovo, , Russia
Clinical Oncology Dispensary of Ministry of Health of Tatarstan
Kazan', , Russia
S-Pb clinical scientific practical center of specialized kinds of medical care (oncological)
Saint Petersburg, , Russia
National University Hospital
Singapore, , Singapore
National Cancer Centre
Singapore, , Singapore
Institute of Oncology Ljubljana
Ljubljana, , Slovenia
National Cancer Center
Goyang-si, , South Korea
Seoul National University Hospital
Seoul, , South Korea
Severance Hospital, Yonsei University Health System
Seoul, , South Korea
Asan Medical Center
Seoul, , South Korea
Samsung Medical Center
Seoul, , South Korea
Hospital Universitario Reina Sofia; Servicio de Oncologia
Córdoba, Cordoba, Spain
Hospital del Mar; Servicio de Oncologia
Barcelona, , Spain
Hospital Univ Vall d'Hebron; Servicio de Oncologia
Barcelona, , Spain
Hospital Duran i Reynals; Oncologia
Barcelona, , Spain
Hospital Universitario 12 de Octubre; Servicio de Oncologia
Madrid, , Spain
Hospital Universitario La Paz; Servicio de Oncologia
Madrid, , Spain
Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia
Málaga, , Spain
Instituto Valenciano Oncologia; Oncologia Medica
Valencia, , Spain
Sodersjukhuset; Onkologkliniken
Stockholm, , Sweden
Akademiska sjukhuset, Onkologkliniken
Uppsala, , Sweden
Universitaetsspital Basel; Onkologie
Basel, , Switzerland
Kantonsspital St.Gallen Brustzentrum/Chirurgie; Brustzentrum
Sankt Gallen, , Switzerland
Universitätsspital Zürich
Zurich, , Switzerland
Kaohsiung Medical Uni Chung-Ho Hospital; Dept of Surgery
Kaohsiung City, , Taiwan
China Medical University Hospital; Surgery
Taichung, , Taiwan
VETERANS GENERAL HOSPITAL; Department of General Surgery
Taipei, , Taiwan
National Taiwan Uni Hospital; General Surgery
Taipei, , Taiwan
Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc
Bangkok, , Thailand
Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology
Bangkok, , Thailand
Songklanagarind Hospital; Department of Oncology
Songkhla, , Thailand
Cukurova Uni Faculty of Medicine; Medical Oncology
Adana, , Turkey (Türkiye)
Istanbul University Cerrahpasa Medical Faculty; Radiation Oncology Department
Istanbul, , Turkey (Türkiye)
Medipol University MF; Oncology Department
Istanbul, , Turkey (Türkiye)
Ege Uni Medical Faculty Hospital; Oncology Dept
Izmir, , Turkey (Türkiye)
Hacettepe Uni Medical Faculty Hospital; Oncology Dept
Sihhiye/Ankara, , Turkey (Türkiye)
Chemotherapy SI Dnipropetrovsk MA of MOHU
Dnipropetrovsk, , Ukraine
Kyiv City Clinical Oncological Center
Kyiv, , Ukraine
Treatment and Prevention Institution Volyn Regional Oncology Dispensary
Lutsk, , Ukraine
Lviv State Oncology Regional Treatment and Diagnostic Centre
Lviv, , Ukraine
Velindre Cancer Centre
Cardiff, , United Kingdom
Western General Hospital; Clinical Oncology
Edinburgh, , United Kingdom
St Bartholomew's Hospital
London, , United Kingdom
Guys ST Thomas Hospital
London, , United Kingdom
Royal Marsden Hospital - London
London, , United Kingdom
Christie Hospital Nhs Trust; Medical Oncology
Manchester, , United Kingdom
Derriford Hospital
Plymouth, , United Kingdom
Royal Preston Hosptial
Preston, , United Kingdom
Weston Park Hospital
Sheffield, , United Kingdom
Royal Marsden Hospital; Dept of Medical Oncology
Sutton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Li M, Yang B. Prognostic Value of NUSAP1 and Its Correlation with Immune Infiltrates in Human Breast Cancer. Crit Rev Eukaryot Gene Expr. 2022;32(3):45-60. doi: 10.1615/CritRevEukaryotGeneExpr.2021040248.
Wang H, Ma H, Sove RJ, Emens LA, Popel AS. Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer. J Immunother Cancer. 2021 Feb;9(2):e002100. doi: 10.1136/jitc-2020-002100.
Adams S, Dieras V, Barrios CH, Winer EP, Schneeweiss A, Iwata H, Loi S, Patel S, Henschel V, Chui SY, Rugo HS, Emens LA, Schmid P. Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer. Ann Oncol. 2020 May;31(5):582-589. doi: 10.1016/j.annonc.2020.02.003. Epub 2020 Feb 20.
Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, Dieras V, Henschel V, Molinero L, Chui SY, Maiya V, Husain A, Winer EP, Loi S, Emens LA; IMpassion130 Investigators. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 Jan;21(1):44-59. doi: 10.1016/S1470-2045(19)30689-8. Epub 2019 Nov 27.
Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Dieras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA; IMpassion130 Trial Investigators. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018 Nov 29;379(22):2108-2121. doi: 10.1056/NEJMoa1809615. Epub 2018 Oct 20.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2014-005490-37
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
WO29522
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.